Cargando…
Immediate Adverse Events Following COVID-19 Vaccination in Australian Pharmacies: A Retrospective Review
Background: Four COVID-19 vaccines are approved for use in Australia: Pfizer-BioNTech BNT162b2 (Comirnaty), AstraZeneca ChAdOx1 (Vaxzevria), Moderna mRNA-1273 (Spikevax), and Novavax NVX-CoV2373 (Nuvaxovid). We sought to examine the type and management of immediate adverse events following immunisat...
Autores principales: | Gallo, Alexander T., Scanlon, Lisa, Clifford, Jade, Patten-Williams, Lawson, Tweedie, Lachlan, Li, Dani, Salter, Sandra M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787804/ https://www.ncbi.nlm.nih.gov/pubmed/36560451 http://dx.doi.org/10.3390/vaccines10122041 |
Ejemplares similares
-
Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations
por: Salter, Sandra M., et al.
Publicado: (2022) -
Active vaccine safety surveillance of seasonal influenza vaccination via a scalable, integrated system in Western Australian pharmacies: a prospective cohort study
por: Salter, Sandra, et al.
Publicado: (2021) -
Use of professional practice guidance resources in pharmacy: a cross-sectional nationwide survey of pharmacists, intern pharmacists, and pharmacy students
por: Mill, Deanna, et al.
Publicado: (2021) -
Implementation of asthma guidelines to West Australian community pharmacies: an exploratory, quasi-experimental study
por: Watkins, Kim, et al.
Publicado: (2016) -
Which Health Impacts of Medical Device Adverse Event Should Be Reported Immediately in Korea?
por: Choi, Sooin, et al.
Publicado: (2022)